[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 159
61. Meng YH, Li S, Hu T, Ma D, Lu YP, Wang H: [Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma]. Chin J Cancer; 2010 Jan;29(1):15-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma].
  • BACKGROUND AND OBJECTIVE: The incidence of cervical adenosquamous carcinoma is relatively low.
  • This study was to analyze the clinicopathologic characteristics and prognostic factors of cervical adenosquamous carcinoma.
  • METHODS: Clinical data of 44 cervical adenosquamous carcinoma patients and 88 cervical adenocarcinoma patients(control), treated from January 2002 to December 2007, were analyzed using Chi-square test, Kaplan-Meier method, log-rank test, and Cox regression model.
  • RESULTS: The proportion of large tumors (maximal diameter > 4 cm) was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (47.7% vs. 28.4%, P<0.05); the proportion of poorly differentiated tumors was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (56.8% vs. 30.7%, P<0.05).
  • CONCLUSIONS: Cervical adenosquamous carcinoma is characterized by large tumor size and poor differentiation.
  • There is no difference in prognosis between cervical adenosquamous carcinoma and cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Kaplan-Meier Estimate. Lung Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Pelvic Neoplasms / secondary. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Tumor Burden


62. Kawamura T, Kanno R, Fujii H, Suzuki T: Expression of liver-type fatty-acid-binding protein, fatty acid synthase and vascular endothelial growth factor in human lung carcinoma. Pathobiology; 2005;72(5):233-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of liver-type fatty-acid-binding protein, fatty acid synthase and vascular endothelial growth factor in human lung carcinoma.
  • OBJECTIVE: A key enzyme of fatty acid synthesis, fatty acid synthase (FAS), is expressed in human cancers, including squamous-cell carcinoma of the lung, and long-chain fatty acids are intracellularly transported and/or taken up from blood by fatty-acid-binding proteins (FABPs).
  • Since the liver-type (L-) FABP, a member of the FABPs, is detected in a subset of gastric adenocarcinomas, the expression of FAS, L-FABP and vascular endothelial growth factor (VEGF) was investigated in human lung carcinomas to elucidate the mechanisms of production and transportation of fatty acid(s) in cancer.
  • METHODS: Expression of L-FABP, FAS and VEGF in 199 surgically resected lung carcinomas was examined immunohistochemically.
  • RESULTS: L-FABP was detected in 60% (120 of 199) of the lung carcinoma cases; detection was increased in large-cell carcinoma (80%) and adenosquamous carcinoma (83%), but low in squamous-cell carcinoma (47%) and in small-cell carcinoma (57%).
  • CONCLUSIONS: L-FABP, FAS and VEGF are highly expressed in human lung cancer, and expression of L-FABP is associated with that of VEGF but not that of FAS, suggesting that L-FABP might be involved in the uptake of fatty acid(s) from the bloodstream.
  • [MeSH-major] Carcinoma / metabolism. Fatty Acid Synthases / metabolism. Fatty Acid-Binding Proteins / metabolism. Lung Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374067.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / FABP1 protein, human; 0 / Fatty Acid-Binding Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.3.1.85 / Fatty Acid Synthases
  •  go-up   go-down


63. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ: Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res; 2006 Jul 1;12(13):4043-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.
  • PURPOSE: Lung cancer is a biologically diverse disease and relevant models reflecting its diversity would facilitate the improvement of existing therapies.
  • With a view to establishing such models, we developed and evaluated xenografts of a variety of human lung cancers.
  • EXPERIMENTAL DESIGN: Using nonobese diabetic/severe combined immunodeficiency mice, subrenal capsule xenografts were generated from primary lung cancer tissue, including moderately and poorly differentiated squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, large cell undifferentiated carcinoma, and carcinosarcoma.
  • Four transplantable lines were developed from rapidly growing tumors (>5 generations), i.e., a small cell lung carcinoma, large cell undifferentiated carcinoma, pulmonary carcinosarcoma, and squamous cell carcinoma.
  • Analyses including spectral karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization, revealed that the xenografts were genetically similar to the original tumors, showing chromosomal abnormalities consistent with karyotypic changes reported for lung cancer.
  • CONCLUSIONS: The subrenal capsule xenograft approach essentially provides a living tumor bank derived from patient material and a means for isolating and expanding specific cell populations.
  • The transplantable tumor lines seem to provide good models for studying various aspects of tumor progression and a platform for developing novel therapeutic regimens, with the possibility of patient-tailored therapies.
  • [MeSH-major] Cell Line, Tumor. Disease Models, Animal. Lung Neoplasms / pathology. Subrenal Capsule Assay


6
Advertisement
4. Piantedosi FV, Caputo F, Mazzarella G, Gilli M, Pontillo A, D'Agostino D, Campbell S, Marsico SA, Bianco A: Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study. Cancer Chemother Pharmacol; 2008 Apr;61(5):803-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
  • To investigate the activity/toxicity of T 175 mg/m2 on day 1, I 3 g/m2 on day 1 (with Mesna uroprotection) and G 1,000 mg/m2 on day 1-8, every 3 weeks in the treatment of advanced/metastatic NSCLC, 46 patients (38 male, 8 female) with NSCLC were enrolled: mean age 58 (range 33-70); Stage IIIB/IV=15/31; ECOG PS 0-1/2=31/15; HISTOLOGY: adenocarcinoma=20, squamous=14, large cell=3, NSCLC=8, adenosquamous=1.
  • Additional non-haematological toxicities were mild nausea, emesis and fatigue.
  • These data suggest future investigations for GIT schedule as a possible alternative to platinum-based regimens in selected advanced/metastatic NSCLC patients where survival, tolerability and quality of life are the primary goals.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639396.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


65. Ma K, Wang TY, He BL, Chang D, Gong M: [Impact of different mediastinal lymphadenectomy on clinical-stage IA non-small cell lung cancer]. Zhonghua Wai Ke Za Zhi; 2008 May 1;46(9):670-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of different mediastinal lymphadenectomy on clinical-stage IA non-small cell lung cancer].
  • OBJECTIVE: To study the role of different lymphadenectomy in the treatment of selected clinical-stage IA non-small cell lung cancer.
  • METHODS: All 115 postoperative patients admitted from January 1997 to May 2002 with pathologic-stage T1 who had been preoperatively diagnosed as clinical-stage I A non-small cell lung cancer were divided into a radical systematic mediastinal lymphadenectomy (LA) group and a mediastinal lymph node sampling (LS) group.
  • In addition, patients with large cell carcinoma and adenosquamous carcinoma were associated with significantly poor 5-year OS (P < 0.05) , and patients with lymph node metastases were associated with poor 5-year OS as well as 5-year DFS (P < 0.01).
  • CONCLUSIONS: After being intraoperatively identified as T1 stage, patients with lesions of more than 2 cm in clinical-stage IA non-small cell lung cancer should be performed with LA to get a better survival, and patients with lesions of 2 cm or less should be performed with LS to decrease invasion.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Node Excision / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956719.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


66. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T: Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol; 2009 Jan;4(1):5-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
  • For lung cancer, MET gene amplification is reported to occur in a subset of adenocarcinomas.
  • Although somatic mutations of MET in lung adenocarcinomas are rare, all but one of those reported so far entail a splice mutation deleting the juxtamembrane domain for binding the c-Cbl E3-ligase; normally such binding leads to ubiquitination and receptor degradation, and loss of this domain leads to MET activation.
  • The purpose of this study was to clarify in the role of MET activation in lung carcinogenesis.
  • MATERIALS AND METHODS: MET gene copy number was determined by real-time quantitative polymerase chain reaction in 187 of the patients with lung cancer and the MET gene splice mutation deleting the juxtamembrane domain was examined by direct sequencing in 262.
  • [MeSH-major] Alternative Splicing. Gene Amplification. Lung Neoplasms / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Receptors, Growth Factor / genetics. Small Cell Lung Carcinoma / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Base Sequence. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Gene Dosage. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Pneumonectomy. Prognosis. Protein Structure, Tertiary. Proto-Oncogene Proteins c-cbl / metabolism. Proto-Oncogene Proteins c-met. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics. Sequence Deletion. Tumor Cells, Cultured. Ubiquitin-Protein Ligases / metabolism. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096300.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.6.5.2 / ras Proteins; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


67. Mao N, Zuo C, Gan N, Zhu J, Huang D, Liu D, Xie T, Pan H, Huang Y: [Trachea-bronchoplasty in the treatment of centrally located lung cancer]. Zhongguo Fei Ai Za Zhi; 2005 Aug 20;8(4):329-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trachea-bronchoplasty in the treatment of centrally located lung cancer].
  • BACKGROUND: To maximize the preservation of functional pulmonary parenchyma and improve the quality of life of patients with centrally located lung cancer, trachea-bronchoplasty has been used in clinical application with good efficacy.
  • The aim of this study is to explore the appropriate admission and management of trachea-bronchoplasty and prevent complications of trachea-bronchial sleeve resection in the treatment of centrally located lung cancer.
  • METHODS: Seventy-six patients with central lung cancer, who were treated with trachea-bronchoplasty from June, 1988 to October, 2004, were analyzed.
  • There were 49 cases of squamous cell carcinoma, 16 adenocarcinoma, 7 adenosquamous carcinoma, 3 small cell lung cancer and 1 adenoid cystic adenocarcinoma.
  • CONCLUSIONS: The trachea-bronchoplasty can not only preserve functional pulmonary parenchyma as much as possible and improve the quality of life of patients, but also provide an operative opportunity to those patients with poor pulmonary function in the treatment of centrally located lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21108894.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Liao QH: [A clinicopathological study of 16 autopsy cases of anthracosilicosis with lung cancer]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2005 Oct;23(5):340-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinicopathological study of 16 autopsy cases of anthracosilicosis with lung cancer].
  • OBJECTIVE: To investigate the clinicopathological characteristics of anthracosilicosis complicated with lung cancer.
  • METHODS: Tissue specimens from 16 autopsy cases of 0(+) anthracosilicosis complicated with lung cancer were retrospectively studied by hematoxylin-eosin, histochemical, and immunohistochemical staining.
  • The pneumoconiosis and dust fibrosis of different degrees in the lung were found.
  • Among 16 cases of lung cancer, there were 5 cases of squamous cell carcinoma, and 5 cases of small cell undifferentiated carcinoma, 3 cases of bronchioloalveolar carcinoma, 2 cases of adenocarcinoma and 1 case of adenosquamous carcinoma.
  • The typical pathological changes of anthracosilicosis complicated with lung cancer were: the cancer tissue was located at the side of coal dust fibrous focus and fibrosis lesion, or mixte with silicotic lesion.
  • CONCLUSIONS: The occurrence of some lung cancer may be related with fibrosis.
  • The dust-exposed workers can suffer from lung cancer which is histologically identical to the general lung tumor.
  • PCNA and Ki67 may be a prognostic index for anthracosilicosis with lung cancer, while vimentin may be a marker for the examination of dust fibrosis in anthracosilicosis.
  • [MeSH-major] Anthracosilicosis / pathology. Lung / pathology. Lung Neoplasms / pathology


69. Damadoğlu E, Aybatli A, Yalçinsoy M, Tahaoğlu C, Atasalihi A, Akkaya E, Yilmaz A: [Adenosquamous carcinoma of the lung (an analysis of 13 cases)]. Tuberk Toraks; 2005;53(2):161-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosquamous carcinoma of the lung (an analysis of 13 cases)].
  • Adenosquamous carcinoma of the lung is a rare disease.
  • In this study, we retrospectively evaluated 13 patients with adenosquamous carcinoma of the lung diagnosed at our center between January 2001 and May 2004.
  • Preoperative pathological diagnosis was squamous cell carcinoma in eight patients, non-small cell lung carcinoma in four patients and adenocarcinoma in one patient.
  • [MeSH-major] Carcinoma, Adenosquamous / epidemiology. Lung Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100653.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


70. Yang HX, Hou X, Lin P, Rong TH, Yang H, Fu JH: [A prognostic analysis of N0-1M0 intralobar metastatic non-small cell lung cancer]. Zhonghua Yi Xue Za Zhi; 2009 Sep 22;89(35):2486-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A prognostic analysis of N0-1M0 intralobar metastatic non-small cell lung cancer].
  • OBJECTIVE: To assess whether it is reasonable to downgrade intralobar metastatic non-small cell lung cancer from T4 disease through a prognostic analysis of N0-1M0 disease.
  • METHODS: A retrospective analysis was conducted to assess the survival of patients with intralobar metastatic non-small cell lung cancer with pathological N0-1M0 disease.
  • The median survival was 24.0 months for patients with adenosquamous carcinoma; while for patients with other pathologic types, the median survival was 48 months.
  • Adenosquamous carcinoma had a shorter survival time than other pathologic types (P = 0.003).
  • The median survival time was 60.0 months for patients undergoing non-pneumonectomy resection and 24 months for patients undergoing pneumonectomy (P = 0.023).
  • CONCLUSION: It is reasonable to downgrade the T4 classification of non-small cell lung cancer with intralobar metastasis.
  • Adenosquamous carcinoma has a poor prognosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


71. Suzuki C, Daigo Y, Ishikawa N, Kato T, Hayama S, Ito T, Tsuchiya E, Nakamura Y: ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res; 2005 Dec 15;65(24):11314-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway.
  • Gene expression profile analysis of non-small cell lung cancers (NSCLC) and subsequent functional analyses revealed that human ANLN, a homologue of anillin, an actin-binding protein in Drosophila, was transactivated in lung cancer cells and seemed to play a significant role in pulmonary carcinogenesis.
  • Immunohistochemical staining of nuclear ANLN on lung cancer tissue microarrays was associated with the poor survival of NSCLC patients, indicating that this molecule might serve as a prognostic indicator.
  • Our data imply that up-regulation of ANLN is a common feature of the carcinogenetic process in lung tissue, and suggests that selective suppression of ANLN could be a promising approach for developing a new strategy to treat lung cancers.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Contractile Proteins / metabolism. Lung Neoplasms / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. rhoA GTP-Binding Protein / metabolism
  • [MeSH-minor] Actins / metabolism. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Movement. Enzyme Activation. Female. Flow Cytometry. Humans. Lung / metabolism. Lung / pathology. Male. Middle Aged. Prognosis. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Survival Rate. Tissue Array Analysis. Tumor Cells, Cultured. Wound Healing

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357138.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Contractile Proteins; 0 / RNA, Small Interfering; 0 / anillin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


72. Nishio M, Matsuda M, Ohyanagi F, Sato Y, Okumura S, Tabata D, Morikawa A, Nakagawa K, Horai T: Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy. Lung Cancer; 2005 Aug;49(2):245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-five patients with advanced non-small cell lung cancer received an antipyrine test and were treated with docetaxel and cisplatin.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antipyrine / pharmacokinetics. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adolescent. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Cisplatin / administration & dosage. Cytochrome P-450 Enzyme System / metabolism. Disease Progression. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neutropenia / chemically induced. Neutropenia / drug therapy. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16022919.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Taxoids; 15H5577CQD / docetaxel; 9035-51-2 / Cytochrome P-450 Enzyme System; Q20Q21Q62J / Cisplatin; T3CHA1B51H / Antipyrine
  •  go-up   go-down


73. Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Wang YP, Jo KH, Moon SW, Song SY, Lee JY, Yoo NJ, Lee SH: ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett; 2006 Jun 8;237(1):89-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
  • Recent reports revealed that the kinase domain of ERBB2 gene, a proto-oncogene, is somatically mutated in the lung adenocarcinomas, suggesting the mutated ERBB2 gene may act as an oncogene in human cancers.
  • The purpose of this was to see whether the ERBB2 kinase domain is mutated in other lung cancer types besides the adenocarcinoma.
  • Here, we performed mutational analysis of the ERBB2 kinase domain by polymerase chain reaction-single strand conformation polymorphism assay in 114 non-adenocarcinoma type non-small cell lung cancers (NSCLCs) tissue samples, including 100 squamous cell carcinomas, three adenosquamous carcinomas and 11 large cell carcinomas.
  • We detected the ERBB2 kinase domain mutation in one squamous cell carcinoma (1.0%).
  • We simultaneously analyzed the somatic mutations of EGFR, K-RAS, PIK3CA and BRAF genes in the squamous cell carcinoma with the ERBB2 mutation, and found that the tumor did not harbor any EGFR or ERBB2 or K-RAS or PIK3CA or BRAF gene mutation, either.
  • This study demonstrated that in addition to lung adenocarcinoma ERBB2 kinase domain mutation could occur in lung squamous cell carcinomas, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations may occasionally contribute to the development of lung squamous cell carcinomas.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Receptor, ErbB-2 / genetics


74. Takahama M, Yamamoto R, Nakajima R, Tsukioka T, Tada H: Pulmonary resection for lung cancer patients on chronic hemodialysis: clinical outcome and long-term results after operation. Interact Cardiovasc Thorac Surg; 2010 Aug;11(2):150-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection for lung cancer patients on chronic hemodialysis: clinical outcome and long-term results after operation.
  • The purpose of this study was to investigate the clinical characteristics of chronic hemodialysis (HD) patients with lung cancer who underwent pulmonary resection at the authors' hospital.
  • Subjects were 24 chronic HD patients (1.1%) from among 2178 patients who underwent pulmonary resection for lung cancer at our hospital between December 1994 and March 2009.
  • Histological diagnoses included squamous cell carcinoma in 12 patients, adenocarcinoma in nine, small cell carcinoma in two and adenosquamous carcinoma in one.
  • Cases of pulmonary resection for lung cancer in chronic HD patients were investigated.
  • [MeSH-major] Lung Neoplasms / surgery. Pneumonectomy. Renal Dialysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20513739.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Wang LJ, Greaves WO, Sabo E, Noble L, Tavares R, Ng T, DeLellis RA, Resnick MB: GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl Immunohistochem Mol Morphol; 2009 Dec;17(6):505-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors.
  • Gross cystic disease fluid protein (GCDFP-15) is currently used as an immunohistochemical marker of breast cancer, whereas thyroid transcription factor (TTF-1) is commonly used as a marker of primary lung neoplasms.
  • Traditionally, a GCDFP-15+/TTF-1- immunohistochemical profile in lung tumors has been considered as highly suggestive of metastatic carcinoma of the breast.
  • Here, we investigated the expression of GCDFP-15 and TTF-1 on a tissue microarray consisting of 381 primary lung carcinomas.
  • Seventeen tumors (4.5%) were positive for GCDFP-15, including 11 of 186 (5.9%) adenocarcinomas, 1 of 97 (1%) squamous cell carcinomas, 1 of 23 (4.3%) carcinoid tumors, 2 of 47 (4.3%) large cell carcinomas, and 2 of 17 (11.8%) adenosquamous carcinomas.
  • Our study confirms that a small subset of primary lung adenocarcinomas exhibits a GCDFP-15 positive phenotype.
  • Thus a GCDFP-15 positive/TTF-1 negative phenotype may not be indicative of metastatic breast carcinoma in every case.
  • It is critical that pathologists be aware of this phenotypic subset of lung adenocarcinomas, especially when faced with small tissue or cytologic samples.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620839.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / Glycoproteins; 0 / PIP protein, human; 0 / TTF1 protein, human
  •  go-up   go-down


76. Kaneda M, Tarukawa T, Watanabe F, Adachi K, Sakai T, Nakabayashi H: Clinical features of primary lung cancer adjoining pulmonary bulla. Interact Cardiovasc Thorac Surg; 2010 Jun;10(6):940-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of primary lung cancer adjoining pulmonary bulla.
  • A few investigators have suggested a possible association between lung cancer and a pulmonary bulla.
  • Five hundred and forty-five cases with primary lung cancer were studied retrospectively by re-evaluation of their chest computed tomography (CT)-scans.
  • Cancer adjoined a bulla in 19 cases.
  • Bulla/cancer incidence was 3.5%.
  • In comparison with the control group, a ratio of squamous cell carcinoma (SCC) and large cell carcinoma was significantly high (P<0.05) and differentiation of the carcinoma was poor (P<0.001).
  • Although the pathological staging and lung function data revealed no statistical difference, the survival curve of bulla/cancer group was significantly worse (P<0.01).
  • Primary lung cancer adjoining pulmonary bulla tends to be poor in prognosis, even if it was small in size.
  • [MeSH-major] Blister / diagnosis. Carcinoma / diagnosis. Lung / pathology. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cell Differentiation. Humans. Incidence. Japan / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Respiratory Function Tests. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20299444.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Kim HK, Choi YS, Kim K, Shim YM, Jeong SY, Lee KS, Kwon OJ, Kim J: Management of ground-glass opacity lesions detected in patients with otherwise operable non-small cell lung cancer. J Thorac Oncol; 2009 Oct;4(10):1242-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of ground-glass opacity lesions detected in patients with otherwise operable non-small cell lung cancer.
  • INTRODUCTION: When pure ground-glass opacity (GGO) lesions are detected in patients with otherwise operable non-small cell lung cancer, it is controversial whether to resect them simultaneously with the primary tumor or not.
  • METHODS: We retrospectively reviewed radiologic features and pathologic diagnoses of pure GGO lesions detected in otherwise operable non-small cell lung cancer.
  • Four of the eight lesions that were simultaneously resected at surgery for the primary tumor turned out to be malignant.
  • CONCLUSIONS: When a pure GGO is detected in otherwise operable lung cancer, it should be resected to rule out the possibility of malignancy if the size is greater than 8 mm.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adult. Aged. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiography, Interventional. Retrospective Studies. Sensitivity and Specificity. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687762.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Lin H, Ma YY, Huang CC, Moh JS, Tsai YM, Changchien CC: Oropharyngeal recurrence after bronchial washing for a lung mass in a patient with cervical cancer. Acta Obstet Gynecol Scand; 2006;85(8):1015-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oropharyngeal recurrence after bronchial washing for a lung mass in a patient with cervical cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / secondary. Lung Neoplasms / secondary. Oropharyngeal Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Bronchoalveolar Lavage. Fatal Outcome. Female. Human papillomavirus 18 / isolation & purification. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / virology


79. Sun Y, Lin H, Zhu Y, Feng J, Chen Z, Li G, Zhang X, Zhang Z, Tang J, Shi M, Hao X, Han H: [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi; 2006 Jun 20;9(3):254-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients].
  • The aim of this study is to observe the clinical anticancer effect of Rg3 in combination with chemotherapy regimen NP (vinorelbine+cisplatin) in advanced non-small cell lung cancer (NSCLC).
  • Types of pathology: adenocarcinoma, 71; squamous cell carcinoma, 29; adenosquamous carcinoma, 8; others, 7.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21172156.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Zhao S, Shao K, Ye B, Liu X, Cheng G, Sun K, Meng P, He J: [Prognostic factors for survival after lung cancer surgery in elderly patients]. Zhongguo Fei Ai Za Zhi; 2007 Oct 20;10(5):391-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors for survival after lung cancer surgery in elderly patients].
  • BACKGROUND: With the improvement of the surgical and anesthetic techniques, there are increasing numbers of elderly surgical patients with lung cancer.
  • METHODS: Data were retrospectively analyzed from 192 patients aged ≥70 years who underwent lung cancer surgery.
  • Tumor characteristics: squamous cell carcinoma 49.0%, adenocarcinoma 35.9%, adenosquamous carcinoma 8.3%, small cell lung cancer 4.7%, others 2.1%.
  • CONCLUSIONS: Thoracic surgery is a safe and feasible approach in elderly patients with lung cancer.
  • More limited lung surgery may be an adequate alternative in patients with associated co-morbidities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21126407.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


81. Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax; 2008 Apr;63(4):352-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas.
  • This study was undertaken to investigate the possibility that overexpression of S100A7 protein might be detected in the sera of patients with lung cancer.
  • METHODS: RNA and protein levels of S100A7 were examined in 60 pairs of frozen lung cancer tissues by RT-PCR and western blot.
  • The specific expression of this protein and its cellular distribution were investigated in 145 paraffin embedded lung cancer samples, six benign lung disease and 21 normal lung tissues by immunohistochemistry.
  • The S100A7 protein level was further analysed in serum from 112 patients with lung cancer, 20 with benign lung diseases and 31 healthy individuals by ELISA.
  • RESULTS: Specific expression of both S100A7 mRNA and protein was found in squamous cell carcinomas, adenosquamous carcinomas and large cell lung carcinomas, whereas neither was detected in adenocarcinomas or paired non-cancerous lung tissues.
  • Further immunohistochemical analysis identified positive staining of S100A7 only in squamous cell carcinomas and large cell lung carcinomas, but not in other subtypes of lung cancer and normal lung tissues.
  • Weak expression was also found in the inflammatory cells of benign lung diseases.
  • Our most important finding is that elevated S100A7 protein could be detected in the sera of patients with squamous cell carcinomas.
  • CONCLUSION: S100A7 was only expressed in squamous cell carcinomas and large cell lung carcinomas and an increase in the level of S100A7 protein in serum may serve as a potential marker for lung cancer diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Calcium-Binding Proteins / metabolism. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364444.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


82. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M: Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia; 2010 Oct;12(10):807-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
  • BACKGROUND AND AIMS: The standard palliative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) is gemcitabine-based chemotherapy; however, PDAC still presents a major therapeutic challenge.
  • We measured hENT1, dCK, CDA, RRM1, and RRM2 messenger RNA (mRNA) levels by quantitative real-time reverse transcription-polymerase chain reaction and determined the combined score (GEM score), based on the expression levels of hENT1, dCK, RRM1, and RRM2, to investigate the association with survival time.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Biomarkers, Tumor / genetics. Carcinoma, Adenosquamous / drug therapy. Deoxycytidine / analogs & derivatives. Gene Expression Regulation, Neoplastic / physiology. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):32-42 [17194903.001]
  • [Cites] N Engl J Med. 2007 Feb 22;356(8):800-8 [17314339.001]
  • [Cites] Dig Surg. 2007;24(2):137-47 [17476103.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Feb;324(2):558-67 [18042828.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):674-9 [18592007.001]
  • [Cites] Anticancer Res. 2008 Jul-Aug;28(4B):2205-12 [18751396.001]
  • [Cites] Cancer Sci. 2008 Nov;99(11):2244-51 [18795940.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):187-95 [18992248.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2913-9 [19318496.001]
  • [Cites] Neoplasia. 2009 Jul;11(7):712-9 [19568416.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Oncogene. 2009 Aug 13;28(32):2903-9 [19543324.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):122-30 [10623702.001]
  • [Cites] Trends Pharmacol Sci. 2001 Aug;22(8):420-6 [11479005.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3263-8 [11595723.001]
  • [Cites] J Mol Diagn. 2003 Feb;5(1):34-41 [12552078.001]
  • [Cites] Semin Surg Oncol. 2003;21(1):19-22 [12923912.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):5000-8 [14581375.001]
  • [Cites] Biochem Pharmacol. 2003 Dec 1;66(11):2185-91 [14609743.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1539-48 [14661056.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3215-22 [15126362.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4215s-4219s [15217961.001]
  • [Cites] Pharmacogenomics J. 2004;4(5):307-14 [15224082.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6956-61 [15501974.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):533-9 [1732039.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1165-9 [9515801.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4349-57 [9766663.001]
  • [Cites] Cancer Lett. 1999 Aug 3;142(2):129-37 [10463768.001]
  • [Cites] Gut. 2005 Mar;54(3):385-7 [15710987.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2285-92 [15788678.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):35-40 [15986033.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):363-70 [15923058.001]
  • [Cites] Lab Invest. 2005 Aug;85(8):1040-50 [15951835.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3928-35 [16585222.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2492-7 [16638857.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1355-63 [17131328.001]
  • (PMID = 20927319.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Equilibrative Nucleoside Transporter 1; 0 / RNA, Messenger; 0 / RRM1 protein, human; 0 / SLC29A1 protein, human; 0 / Tumor Suppressor Proteins; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / ribonucleotide reductase M2; EC 1.17.4.1 / Ribonucleoside Diphosphate Reductase; EC 2.7.1.74 / Deoxycytidine Kinase; EC 3.5.4.5 / Cytidine Deaminase
  • [Other-IDs] NLM/ PMC2950330
  •  go-up   go-down


83. Gao YS, Zhang DC, He J, Sun KL, Zhang DW, Zhang RG: [Diagnosis and surgical treatment for stage I non-small-cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2005 Jan;27(1):52-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical treatment for stage I non-small-cell lung cancer].
  • OBJECTIVE: To evaluate the results of surgery and the diagnosis of stage I non-small-cell lung cancer (NSCLC).
  • The 5-year survival rates for patients with squamous-cell carcinoma, adenocarcinoma, adenosquamous and alveolar-cell carcinoma were 73.3%, 55.3%, 52.2%, 71.7%, respectively.
  • The 1-, 3-, 5-year survival rates for T1N0 were 95.0%, 83.2%, 74.3% whereas those of T2N0 lung lesions were 90.8%, 75.9%, 59.9% (P < 0.05).
  • CONCLUSION: The 5-year survival rate of pathologic stage I non-small-cell lung cancer is 66.1%.
  • The outcome of patients with squamous-cell carcinoma (73.3%) is similar to that of alveolar-cell carcinoma (71.7%) which, however, is better than that of adenocarcinoma (55.3%) or adenosquamouscarcinoma (52.5%).
  • Regular lobectomy plus radical mediastinal lymph node dissection is the appropriate management for stage I non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771801.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


84. Chang YL, Wu CT, Lee YC: Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg; 2007 Sep;134(3):630-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients.
  • OBJECTIVES: According to our previous study, the concurrent detection of p53 and epidermal growth factor receptor mutations significantly improves the clonality assessment and impact management of patients with multiple primary lung cancer.
  • METHODS: A database of 1651 patients was evaluated for unilateral and bilateral synchronous multiple primary lung cancers.
  • RESULTS: The 5-year survival for all synchronous multiple primary lung cancers was 35.3%.
  • Notably, lymph node metastasis, extranodal extension, vascular invasion, tumors with adenosquamous carcinoma or different histology, and poor survival were observed.
  • CONCLUSION: An aggressive surgical approach is safe and justified in patients with synchronous multiple primary lung cancers and node-negative diseases.
  • The status of this particular form of non-small cell lung cancers might be considered in the conventional TNM staging system for more accurate prediction of patient prognosis.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Cardiovasc Surg. 2008 Aug;136(2):542
  • (PMID = 17723810.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Mori T, Nomori H, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, Yamashita Y: Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol; 2008 Apr;3(4):358-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FDG uptake of each lesion was quantitatively measured by a contrast ratio of standard uptake value (SUV-CR) between the lesions and contralateral lung.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Lung Neoplasms / diagnosis. Positron-Emission Tomography / methods. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnostic Imaging. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Prognosis. Prospective Studies. ROC Curve. Sensitivity and Specificity. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379353.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


86. Ventsiavichius V, Tsitsenas S, Tikuĭshis R: [Potentialities of surgical treatment for concomitance of pulmonary tuberculosis and lung cancer]. Probl Tuberk Bolezn Legk; 2007;(5):32-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Potentialities of surgical treatment for concomitance of pulmonary tuberculosis and lung cancer].
  • The paper deals with the important problem of pulmonary surgery--the capacities of surgical treatment in concomitance of pulmonary tuberculosis and lung cancer.
  • In 1990 to 2002, the Santarishkes Republican Tuberculosis and Lung Diseases Hospital and the Department of Thoracic Surgery and Oncology, Vilnius University Cancer Institute operated on 2218 patients with lung cancer, of them 46 (2.1%) were diagnosed as having concomitance of lung cancer and tuberculosis.
  • The diagnosis of central and peripheral lung cancer was established in 37 (80.4%) and 9 (19.6%) patients, respectively.
  • Histology revealed squamous-cell tumors in 24 (52.2%) patients, adenocarcinoma in 10 (21.7%), and adenosquamous-cell carcinomas in 12 (26.1%) patients.
  • Surgery is the method of choice in the treatment of concomitance of pulmonary tuberculosis and lung cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / complications. Lung Neoplasms / surgery. Tuberculosis, Pulmonary / complications

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598460.001).
  • [ISSN] 1728-2993
  • [Journal-full-title] Problemy tuberkuleza i bolezneĭ legkikh
  • [ISO-abbreviation] Probl Tuberk Bolezn Legk
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


87. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G: Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res; 2008 Nov 15;14(22):7430-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.
  • PURPOSE: In carcinomas, invasive tumor growth is accompanied by desmoplastic stroma reaction and facilitated by epithelial-mesenchymal transition (EMT) of cancer cells.
  • We investigated the prognostic significance of the EMT indicator proteins periostin and vimentin in comparison with versican, a putative indicator of the opposite mechanism mesenchymal-epithelial transition (MET), and to the desmoplasia proteins collagen and elastin in non-small cell lung cancer (NSCLC).
  • RESULTS: Of the 533 patients, 48% had squamous cell carcinoma, 47% adenocarcinoma, and 5% adenosquamous carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Adhesion Molecules / biosynthesis. Lung Neoplasms / metabolism. Vimentin / biosynthesis
  • [MeSH-minor] Age Factors. Aged. Cell Differentiation / physiology. Collagen / biosynthesis. Elastin / biosynthesis. Epithelial Cells / metabolism. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mesoderm / metabolism. Middle Aged. Prognosis. Sex Factors. Tissue Array Analysis. Versicans / biosynthesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010860.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / Vimentin; 126968-45-4 / Versicans; 9007-34-5 / Collagen; 9007-58-3 / Elastin
  •  go-up   go-down


88. Satoh M, Wakabayashi O, Araya Y, Jinushi E, Yoshida F: [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):798-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor].
  • Chest X-ray revealed multiple emphysematous bullae in both lungs and a tumor shadow in the right upper lobe.
  • The tumor was diagnosed as a non-small-cell lung cancer with direct invasion to the adjacent rib.
  • Autopsy revealed multiple emphysematous bullae, poorly differentiated adenosquamous cell carcinoma of the lung, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor.
  • This case suggests the possibility that von Recklinghausen's disease associated with emphysematous bullae is a risk factor for lung cancer.
  • Although von Recklinghausen's disease is reportedly associated with various malignant tumors, it is quite rare for von Recklinghausen's disease to be associated with triple non-neurogenic tumors.
  • [MeSH-major] Autopsy. Carcinoid Tumor / etiology. Carcinoma, Adenosquamous / etiology. Duodenal Neoplasms / etiology. Gastrointestinal Stromal Tumors / etiology. Lung Neoplasms / etiology. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Pulmonary Emphysema / complications. Pulmonary Emphysema / diagnosis. Pulmonary Emphysema / pathology. Risk Factors


89. Varlotto JM, Recht A, Nikolov M, Flickinger JC, Decamp MM: Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer; 2009 Feb 15;115(4):851-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer.
  • BACKGROUND: It is uncertain whether lymphadenectomy (LA) affects overall survival (OS) or disease-free survival (DFS) rates for patients with stage I nonsmall cell lung cancer (NSCLC), as is the optimal number of lymph nodes that should be recovered.
  • For patients diagnosed from 1998 to 2002 undergoing only N1 or only N2 dissections, LA was also associated with statistically significant improvements in OS in both groups and a significant difference and trend for improved DFS in the 2 groups, respectively.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymph Node Excision
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. SEER Program. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19140203.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Kim MS, Koh JS, Baek HJ, Ryoo BY, Kim CH, Lee JC: Neoplastic fever caused by lung cancer. J Thorac Oncol; 2007 Feb;2(2):158-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic fever caused by lung cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / complications. Fever / etiology. Lung Neoplasms / complications

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410033.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Picozzi G, Paci E, Lopez Pegna A, Bartolucci M, Roselli G, De Francisci A, Gabrielli S, Masi A, Villari N, Mascalchi M: Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ''Italung-CT''. Radiol Med; 2005 Jan-Feb;109(1-2):17-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ''Italung-CT''.
  • PURPOSE: To report the results of a three-year observational pilot study of lung cancer screening with low dose computed tomography (CT) and to present the study design of a randomised clinical trial named as ''Italung-CT''.
  • Indeterminate nodules were managed according to the recommendations of the Early Lung Cancer Action Project.
  • One (1.6%) prevalent lung cancer (adenosquamous carcinoma) and one (2.2%) incident lung cancer (small cell cancer at the first annual examination) were observed, as well as a pulmonary localisation of Hodgkin's lymphoma (at the second annual test).
  • In addition, one subject underwent lung surgery for a chondromatous hamartoma.
  • [MeSH-major] Lung Neoplasms / radiography. Tomography, Spiral Computed
  • [MeSH-minor] Female. Humans. Lung / radiography. Male. Middle Aged. Pilot Projects. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15729183.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


92. Carvalho L: Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol; 2009 Nov-Dec;15(6):1101-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry.
  • The current state of molecular knowledge on lung cancer demands a histological classification which goes beyond small-cell and non-small-cell carcinoma to provide support for tailored therapy in aiding in understanding of the drugs currently available.
  • As diagnosis and follow-up in the vast majority of lung cancer cases is based on biopsies and cytology samples, Immunohistochemical Bronchial Pulmonary Carcinoma Classification (IBPCC) is necessary to reveal the raft of characteristics available.
  • The immunohistochemical panel clarifies the main morphology and cytology characteristics to maintain the leading histological types as squamous cell carcinoma (high weight molecular cytokeratins/HWMC), adenosquamous carcinoma (CK7, TTF1, HWMA), neuroendocrine carcinoma (Chrg, Syn, CD56, TTF1, Ki67), adenocarcinoma (CK7, CK20, TTF1) and bring the polymorphic and pleomorphic carcinomas under a single banner of pleomorphic carcinoma (Ck7, TTF1, HWMC, VMT, Desmin, Actin) which shelters large cell carcinomas and sarcomatoid carcinomas.
  • Lung cancer chemotherapy will still be based on platinum and gemcitabine for the near future and the IBPCC is a simple and efficient tool for streamlining the registration of lung cancer histological characteristics in biopsies and other reduced samples to support clinical evidence and trials.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Bronchial Neoplasms / classification. Bronchial Neoplasms / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859629.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Portugal
  • [Number-of-references] 80
  •  go-up   go-down


93. Nambu A, Kato S, Sato Y, Okuwaki H, Nishikawa K, Saito A, Matsumoto K, Ichikawa T, Araki T: Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET. Ann Nucl Med; 2009 May;23(3):269-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET.
  • PURPOSE: To evaluate the relationship between SUVmax of primary lung cancers on FDG-PET and lymph node metastasis.
  • METHOD AND MATERIALS: The subjects were a total of consecutive 66 patients with lung cancer who were examined by FDG-PET and subsequently underwent surgery between October 2004 and January 2008.
  • The pathological subtypes of the lung cancers consisted of 49 adenocarcinomas, 11 squamous cell carcinomas, 2 adenosquamous carcinoma, 1 large cell carcinoma, 1 small cell carcinoma, 1 pleomorphic carcinoma and 1 mucoepidermoid carcinoma.
  • We statistically compared (1) the mean SUVmax of lung cancer between the groups with and without lymph node metastasis (2) the frequency of lymph node metastasis between higher and lower SUVmax of lung cancer groups that were classified by using the median SUVmax of lung cancer, and (3) evaluated the relationship between the SUVmax of lung cancer and frequency of lymph node metastases, and (4) correlations between the SUVmax of lung cancer and number of the metastatic lymph nodes and pathological n stages.
  • RESULTS: The difference in the average of the SUVmax of lung cancer between the cases with and without lymph node metastases was statistically significant (p = 0.00513).
  • Lymph node metastasis was more frequently seen in the higher SUVmax of lung cancer group (17/33, 52%) than in the lower SUVmax of lung cancer group (7/33, 21%) with a statistically significant difference.
  • There was no lymph node metastasis in lung cancers with an SUVmax of lung cancer less than 2.5, and lung cancers with an SUVmax of lung cancer more than 12 had a 70% frequency of lymph node metastasis.
  • There were moderate correlations between SUVmax of lung cancer, and the number of the metastatic lymph nodes (gamma = 0.404, p = 0.001) and pathological n stage (gamma = 0.411, p = 0.001).
  • CONCLUSIONS: The likelihood of lymph node metastasis increases with an increase of the SUV of a primary lung cancer.
  • [MeSH-major] Fluorodeoxyglucose F18 / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19340527.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


94. Uramoto H, Yamada S, Hanagiri T: Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res; 2010 Nov;30(11):4717-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung.
  • The aim of this study was to detect the deltaNp63 expression in the squamous carcinoma component of adenosquamous carcinoma and evaluate its usefulness as a specific squamous carcinoma marker.
  • PATIENTS AND METHODS: Immunohistochemistry was used to analyze the protein expression of deltaNp63 and high molecular weight cytokeratin in paraffin-embedded tumor samples from 17 patients with well-characterized adenosquamous carcinoma.
  • It was easy to discriminate the squamous carcinoma and adenocarcinoma components in all tumors.
  • CONCLUSION: These findings indicated that the deltaNp63 status was useful for distinguishing squamous carcinoma from adenocarcinoma in formalin-postfixed adenosquamous carcinoma specimens.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115930.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


95. Xu JB, Bao Y, Liu X, Liu Y, Huang S, Wang JC: Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma. Lung Cancer; 2007 Oct;58(1):36-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma.
  • Large cell carcinoma (LCC) of the lung is defined as an undifferentiated carcinoma without the characteristic features of squamous cell (SqC), small cell, or adenocarcinomas (AdC).
  • In the present study, the expression level of the important tumor suppressor, transforming growth factor beta type II receptor (TGFBR2), was examined both in LCC and non-LCC tumors, which include AdC, SqC and adenosquamous carcinoma (Ad-SqC).
  • Immunohistochemical staining with TGFBR2 antibody revealed statistically significant or near significant differences in the reduced expression in LCC (80% of cases) versus AdC (42.1% of cases, P=0.0288) and SqC (47.1% of cases, P=0.0589), or LCC versus non-LCC (45% of cases, P=0.02).
  • The differences in the expression level of TGFBR2 between LCC and non-LCC were consistent with the histopathologic classification of these tumors, suggesting that the defective TGFBR2 expression might contribute to the carcinogenesis and/or development of LCC.
  • [MeSH-major] Carcinoma, Large Cell / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Protein-Serine-Threonine Kinases / biosynthesis. Receptors, Transforming Growth Factor beta / biosynthesis
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Biomarkers, Tumor. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Male. Middle Aged. Mutation. Neoplasm Staging

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17566598.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Transforming Growth Factor beta; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


96. Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N: Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins. Tumori; 2007 Sep-Oct;93(5):473-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
  • AIMS AND BACKGROUND: Lung cancer is one of the most common cancers and has became a predominant cause of cancer-related death throughout the world.
  • The k-ras codon 12 mutation, which is the most common lung cancer mutation, is found in 15 to 30% of all lung cancers.
  • Furthermore, the p53 gene has a very important role in the biological properties of tumor cells, and it is mutated in about 50% of non-small cell lung cancers.
  • METHODS: In the present study, we examined p53 gene mutations and k-ras codon 12 mutations from the tumor samples and surgical margins of 34 non-small-cell lung cancer patients.
  • RESULTS: A p53 mutation was detected only in primary tumors of 3 out of 34 patients (8.82%).
  • Moreover, a k-ras codon 12 mutation was detected in both the primary tumor and the surgical margin tissues of 2 out of 34 patients (5.88%).
  • We think that different mechanisms related to other genes and individual genetic differences might play a role in cancer formation in our study group.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Protein p53 / genetics. ras Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Codon / genetics. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Prognosis. Proto-Oncogene Proteins p21(ras). Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038880.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


97. Koshimune R, Aoe M, Toyooka S, Hara F, Ouchida M, Tokumo M, Sano Y, Date H, Shimizu N: Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer; 2007;7:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
  • Recently, YM529 as well as other third-generation BPs have also been shown to exert anti-tumor effects against various types of cancer cells both in vitro or/and in vivo.
  • In this study, we investigate the anti-tumor effect of YM529 on non-small cell lung cancer (NSCLC).
  • METHODS: Direct anti-tumor effect of YM529 against 8 NSCLC cell lines (adenocarcinoma: H23, H1299, NCI-H1819, NCI-H2009, H44, A549, adenosquamous cell carcinoma: NCI-H125, squamous cell carcinoma: NCI-H157) were measured by MTS assay and calculated inhibition concentration 50 % (IC50) values.
  • RESULTS: We found that there was direct anti-tumor effect of YM529 on 8 NSCLC cell lines in a dose-dependent manner and their IC50 values were 2.1 to 7.9 microM and YM529 induced apoptosis and G1 arrest cell cycle with dose-dependent manner and YM529 caused down regulation of phospholyration of ERK1/2 in signaling pathways of NSCLC cell line (NCI-H1819).
  • CONCLUSION: Our study demonstrate that YM529 showed direct anti-tumor effect on NSCLC cell lines in vitro, which supports the possibility that third-generation BPs including YM529 can be one of therapeutic options for NSCLC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Diphosphonates / pharmacology. Imidazoles / pharmacology. Lung Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans


98. Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J; 2005 Sep;98(9):946-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four primary tumors of lung, bladder, prostate, and breast in a male patient.
  • It is a case of both synchronous and metachronous primary malignant neoplasms occurring in four different organs.
  • Immunohistochemical stains showed tumor cell nuclei to be negative for p53 over-expression.
  • To our knowledge, this is the first documented case with this combination of primary tumors.
  • The tumors included an adenosquamous cell carcinoma of the lung, transitional cell carcinoma of the urinary bladder, and adenocarcinomas of the prostate and the breast.
  • We also review the medical literature for the possible causes of multiple primary malignant neoplasms.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma / complications. Lung Neoplasms / complications. Prostatic Neoplasms / complications. Urologic Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Shock, Septic / complications. Spinal Neoplasms / complications. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Urinary Diversion


99. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C, BO17704 Study Group: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol; 2010 Sep;21(9):1804-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
  • BACKGROUND: Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical benefit when combined with platinum-based chemotherapy in first-line advanced non-small-cell lung cancer.
  • Primary end point was progression-free survival (PFS); OS was a secondary end point.
  • CONCLUSIONS: Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin-gemcitabine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Placebos. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):263-73 [18772115.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3909-17 [14581415.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):69-80 [15603856.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7889-96 [16204015.001]
  • (PMID = 20150572.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00806923
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Placebos; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC2924992
  •  go-up   go-down


100. Zhang BS, Yu CH, Zhang YM, Yu JQ, Zhou NK: [Prognostic analysis of partial atrium or large blood vessel resection for treatment of locally advanced lung cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov;30(11):2509-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of partial atrium or large blood vessel resection for treatment of locally advanced lung cancer].
  • OBJECTIVE: To explore the value of partial atrium or large blood vessel resection for the treatment of locally advanced lung cancer.
  • METHODS: Thirty-five patients with locally advanced lung cancer (T(4)N(0)-N(2)M(0)) underwent lobectomy or pneumonectomy combined with intrapericardial vascular management or partial resection of the atrium.
  • Of the 35 patients , 15 underwent left pneumonectomy combined with partial resection of the left atrium, 3 had pneumonectomy and partial resection of pulmonary artery trunk, 11 received right pneumonectomy and partial resection of the left atrium, 3 had middle and lower lobectomies and partial resection of the left atrium, and 3 underwent right upper lobectomy, partial resection of the superior vena cava and replacement of artificial blood vessel.
  • Pathologically, 27 patients had squamous carcinoma, 3 had adenocarcinoma, 3 had adenosquamous carcinoma and 2 had large cell carcinoma.
  • CONCLUSION: Pneumonectomy or lobectomy combined with intrapericardial vascular management or partial resection of the atrium can enhance the possibility of radical resection of locally advanced lung cancer and increase the long term survival rate.
  • [MeSH-major] Heart Atria / surgery. Lung Neoplasms / surgery. Vena Cava, Superior / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21097419.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement